Edwin de Graaf - Gilde Healthcare

team
Venture&Growth

All team members
Edwin de Graaf
Managing Partner
healthtech / therapeutics
The Netherlands

Edwin de Graaf

Managing Partner

Edwin de Graaf is founder and managing partner of Gilde Healthcare. Edwin joined Gilde in 1997 following a career of 3 years as a tax consultant with Coopers & Lybrand (now PwC). He is co-responsible for fund management and investment activities of the healthcare venture and growth capital funds and is head of responsible and impact investment.

Edwin de Graaf is a Dutch national and holds a master’s degree in Business and Fiscal Economics from the Erasmus University Rotterdam. He led investments in AM-Pharma (sale minority interest and option agreement with Pfizer), GlycArt (trade sale to Roche), IDEA (license to Alpharma Pharmaceuticals), Omegatech (trade sale to Martek Biosciences, now DSM), Pieris Pharmaceuticals Inc. (Nasdaq: PIRS), Prosonix (trade sale to Circassia), Sanifit Therapeutics, Santaris Pharma (trade sale to Roche), uniQure (Nasdaq: QURE) and WITHINGS and was involved with investments and divestments including Ascendis Pharma (Nasdaq: ASND), Definiens (trade sale to AZ/MedImmune), Moximed, ProQr (Nasdaq: PRQR), ProFibrix (trade sale to The Medicines Company) and Sapiens (trade sale to Medtronic). He represented Gilde on the boards of AM Pharma, Ascendis Pharma, Glycart, IDEA, Pieris, Prosonix, Sanifit Therapeutics, Santaris Pharma and uniQure and currently serves on the board WITHINGS.

Stefan Luzi

Partner Therapeutics
Venture&Growth
Stefan Luzi joined Gilde Healthcare in 2015. He is focusing on venture and growth capital investments in the biopharmaceutical sector. He led several investments and currently represents Gilde on the boards of Lava Therapeutics B.V....

Henry Zubaida

Senior Associate Healthtech
Venture&Growth
Henry joined Gilde Healthcare in 2018 and focuses on the Healthtech sector. He has been involved in several investments including Big Health, Withings and Volta Medical. He is a board observer at FIRE1, Withings and...

Dr. Paul Parren

Operational Partner
Paul Parren is an internationally recognized antibody drug innovator and developer. Paul was Head of Preclinical Development and Research at Genmab (2002-2017), translating antibody biology successfully into immunotherapies from discovery to the clinic, including approved...